Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00803920 · ClinicalTrials.gov registry record
Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes Taking Twice-Daily Exenatide or Once-Weekly Exenatide
A clinical trial, sponsored by HealthPartners Institute.
- Completed
- Registry status
- 8
- Enrollment target
NCT00803920: Completed study, sponsored by HealthPartners Institute.
NCT00803920 is a clinical trial that has completed, run by HealthPartners Institute. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00803920 has completed, sponsored by HealthPartners Institute.
- COMPLETED
- Registry status
- 8 participants
- Enrollment target
Study Summary
The purpose of this substudy is to obtain CGM data from individuals taking exenatide. The CGM measurements gathered before starting and during treatment with exenatide IR and/or exenatide LAR will help determine the characteristics of glucose control during treatment.
Primary Outcome
Baseline CGM will be performed from Visit 2 to Visit 3 for approximately 14 days followed by a second CGM period from Visit 3 to Visit 6 for approximately 17 days. At Week 28, two weeks after Visit 14 (Week 26), subjects will be instructed to begin CGM and to continue through Visit 20 (Week 30) for Group A subjects or Visit 22 (Week 32) for Group B subjects. At Week 50, two weeks after Visit 28 (Week 48), subjects will be instructed to begin the final CGM period and to continue monitoring until
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2006-12 |
| Est. Completion | 2008-02 |
What the finished NCT00803920 record still lists
NCT00803920 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 8 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00803920 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00803920 about?
NCT00803920 is a clinical study titled "Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes Taking Twice-Daily Exenatide or Once-Weekly Exenatide". The purpose of this substudy is to obtain CGM data from individuals taking exenatide. The CGM measurements gathered before starting and during treatment with exenatide IR and/or exenatide LAR will help determine the characteristics of glucose control during treatment.
What is the current status of trial NCT00803920?
This trial is currently completed. The enrollment target is 8 participants. The study started on 2006-12. Estimated completion is 2008-02.
Who is sponsoring clinical trial NCT00803920?
This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia